The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
MetadataShow full item record
AuthorTorrente López, Anabel; Hermosilla, Jesús; Navas Iglesias, Natalia Africa; Cuadros Rodríguez, Luis; Cabeza, José; Salmerón García, Antonio
COVID-19 treatmentClinical trialsMonoclonal antibodiesNon-SARS-CoV-2 specificSARS-CoV-2 specific
Torrente-López, A... [et al.]. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines 2021, 9, 557. [https://doi.org/10.3390/vaccines9060557]
SponsorshipInstitute of Health 'Carlos III', Ministry of Economy and Competitiveness, Spain - European Regional Development Funds (ERDF) FIS: PI-17/00547
Major efforts have been made in the search for effective treatments since the outbreak of the COVID-19 infection in December 2019. Extensive research has been conducted on drugs that are already available and new treatments are also under development. Within this context, therapeutic monoclonal antibodies (mAbs) have been the subject of widespread investigation focusing on two target-based groups, i.e., non-SARS-CoV-2 specific mAbs, that target immune system responses, and SARS-CoV-2 specific mAbs, designed to neutralize the virus protein structure. Here we review the latest literature about the use of mAbs in order to describe the state of the art of the clinical trials and the benefits of using these biotherapeutics in the treatment of COVID-19. The clinical trials considered in the present review include both observational and randomized studies. We begin by presenting the studies conducted using non-SARS-CoV-2 specific mAbs for treating different immune disorders that were already on the market. Within this group of mAbs, we focus particularly on anti-IL-6/IL-6R. This is followed by a discussion of the studies on SARS-CoV-2 specific mAbs. Our findings indicate that SARS-CoV-2 specific mAbs are significantly more effective than non-specific ones.